Bristol-Myers Squibb Completes Divestment of UPSA
01 Juli 2019 - 11:17AM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) announced today that
effective July 1, 2019 it has completed its previously announced
divestment of its consumer health business, UPSA, to Taisho
Pharmaceutical Co., Ltd (Taisho), the largest over-the-counter drug
company in Japan.
The divestiture is part of Bristol-Myers Squibb’s strategy to
simplify and to realign its business portfolio to address changes
in its business and the future requirements of its evolving
pipeline. UPSA is focused on delivering important consumer
medicines in France, across Europe and additional countries that
are outside of the Bristol-Myers Squibb core focus. The Company is
focusing resources on its highest priorities of discovering,
developing and delivering transformational medicines for patients
facing serious diseases.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube and Facebook.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, the research, development and
commercialization of pharmaceutical products and the transaction.
All statements that are not statements of historical facts are, or
may be deemed to be, forward-looking statements. Such
forward-looking statements are based on historical performance and
current expectations and projections about our future financial
results, goals, plans and objectives and involve inherent risks,
assumptions and uncertainties, including internal or external
factors that could delay, divert or change any of them in the next
several years, that are difficult to predict, may be beyond our
control and could cause our future financial results, goals, plans
and objectives to differ materially from those expressed in, or
implied by, the statements. These risks, assumptions, uncertainties
and other factors include, among others, any delay or inability of
Bristol-Myers Squibb to realize the expected benefits of the
transaction. No forward-looking statement can be guaranteed.
Forward-looking statements in this press release should be
evaluated together with the many risks and uncertainties that
affect Bristol-Myers Squibb's business and market, particularly
those identified in the cautionary statement and risk factors
discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for
the year ended December 31, 2018, as updated by our subsequent
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and
other filings with the Securities and
Exchange Commission. The forward-looking statements included in
this document are made only as of the date of this document and
except as otherwise required by applicable law, Bristol-Myers
Squibb undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events, changed circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190701005381/en/
Media: U.S. – Priyanka Shah, +1-609-252-7602,
Priyanka.shah1@bms.com France – Frederique Saas, +33 6 18 45 09 42,
frederique.saas@bms.com Japan – Erika Nakajima, +81 3-6705-7790,
erika.nakajima@bms.com
Investors: Tim Power, +1-609-252-7509,
timothy.power@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Apr 2023 bis Apr 2024